Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Colon Cleaning after Inadequate Bowel Preparation: A Pooleddata Analysis.

Journal of gastrointestinal and liver diseases : JGLD·2026
Same author

Gastric cancer secondary prevention in dyspeptic patients.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

Risk Factors Associated with Adenomas or Serrated Polyps in Patients who Underwent Screening Colonoscopy.

Journal of gastrointestinal and liver diseases : JGLD·2026
Same author

Accuracy of a new innovative column-free miniaturized gas-mass spectrometer compared with a classic gas-mass spectrometer to diagnose and monitor Helicobacter pylori infection: a prospective single blind study.

European journal of gastroenterology & hepatology·2026
Same author

Empirical first- and second-line eradication regimens for Helicobacter pylori adult-infected patients: a National Survey among Italian gastroenterologists and general practitioners.

European journal of gastroenterology & hepatology·2026
Same author

Diagnostic accuracy of non-invasive tests for helicobacter pylori infection in children: A multicenter retrospective study by SIGENP.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2025

Related Experiment Video

Updated: May 18, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Helicobacter pylori therapy: Present and future.

Vincenzo De Francesco1, Enzo Ierardi, Cesare Hassan

  • 1Vincenzo De Francesco, Enzo Ierardi, Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Ospedali Riuniti, 71100 Foggia, Italy.

World Journal of Gastrointestinal Pharmacology and Therapeutics
|September 12, 2012
PubMed
Summary
This summary is machine-generated.

Helicobacter pylori (H. pylori) eradication therapy faces challenges due to treatment failures. This review examines bacterial and host factors influencing treatment success and evaluates current leading regimens like sequential and concomitant therapies.

Keywords:
Antibiotic resistanceEradicationHelicobacter pyloriTherapyVirulence factors

More Related Videos

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance
06:40

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance

Published on: July 28, 2023

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology
05:13

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

Related Experiment Videos

Last Updated: May 18, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance
06:40

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance

Published on: July 28, 2023

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology
05:13

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

Area of Science:

  • Gastroenterology
  • Microbiology
  • Oncology

Background:

  • Helicobacter pylori (H. pylori) infection is a primary cause of chronic gastritis, peptic ulcers, gastric MALT lymphoma, and gastric cancer.
  • Current first-line H. pylori eradication therapies exhibit variable success rates, posing a clinical challenge.
  • Understanding factors contributing to treatment failure is crucial for optimizing H. pylori eradication strategies.

Purpose of the Study:

  • To review bacterial and host factors implicated in H. pylori treatment failure.
  • To evaluate the efficacy of current leading H. pylori eradication regimens, specifically sequential and concomitant therapies.

Main Methods:

  • Comprehensive literature review of studies on H. pylori infection and treatment.
  • Analysis of factors affecting H. pylori eradication based on bacterial characteristics and host responses.
  • Evaluation of clinical data for sequential and concomitant therapy regimens.

Main Results:

  • Identified key bacterial factors (e.g., antibiotic resistance) and host factors (e.g., adherence, comorbidities) influencing H. pylori eradication.
  • Sequential and concomitant therapies demonstrate improved H. pylori eradication rates compared to standard triple therapy in various settings.
  • These advanced regimens offer promising alternatives for overcoming treatment resistance.

Conclusions:

  • Optimizing H. pylori treatment requires a thorough understanding of both bacterial and host-related factors.
  • Sequential and concomitant therapies represent more effective strategies for H. pylori eradication, addressing current therapeutic limitations.
  • Further research into personalized treatment approaches based on identified factors is warranted to improve patient outcomes.